Press Releases Akeso, Inc.

Equities

9926

KYG0146B1032

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. Other stock markets 01:38:08 17/07/2025 pm IST			5-day change	1st Jan Change
139.50 ^HKD	+10.71%		+27.05%	+129.82%

16/07	Akeso, Inc. Announces First Patient Enrolled in the Phase III Trial (AK112-312/HARMONi-GI6) of Ivonescimab for First-Line Treatment of Advanced Metastatic Colorectal Cancer	CI
03/07	Summit, AstraZeneca in talks over $15 billion cancer drug licensing deal, Bloomberg News reports	RE

Press Releases

Akeso Announces First Patient Enrolled in the Phase III Trial(AK112-312/HARMONi-GI6)of Ivonescimab for First-Line Treatment of Advanced Metastatic Colorectal Cancer	16/07	AQ
Akeso Announces First Patient Enrolled in the Phase III Trial（AK112-312/HARMONi-GI6）of Ivonescimab for First-Line Treatment of Advanced Metastatic Colorectal Cancer	16/07	PR
Akeso's First Bispecific ADC Enters Clinical Trials, Strengthening Leadership in 'IO+ADC' 2.0 Strategy	04/07	AQ
Akeso's PD-1/CTLA-4 Bispecific Antibody Cadonilimab Approved for First-Line Treatment of Cervical Cancer in All-Comer Populations--Third Approved Indication for Cadonilimab	05/06	PR
Summit Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Ivonescimab in Combination with Pfizer Antibody Drug Conjugates	25/02	AQ
Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs	25/02	PR
Akeso to Present at Citi 2024 Global Healthcare Conference and the 7th Annual Evercore HealthCONx Conference	29/11	AQ
Summit Therapeutics to Host Third Quarter 2024 Financial Results and Operational Progress Call on October 30, 2024	24/24/24	AQ
IGCS Late Breaking Abstract and the Lancet, Akeso Published Positive PFS and OS Results from Phase 3 First-Line Study of Cadonilimab in Cervical Cancer	17/24/17	AQ
Summit Therapeutics - Ivonescimab Monotherapy Reduced the Risk of Disease Progression or Death by 49% Compared to Pembrolizumab Monotherapy in First-Line Treatment of Patients with PD-L1 Positive Advanced NSCLC in China	09/24/09	AQ
Summit Therapeutics Inc. - HARMONi-2, Featuring Ivonescimab Monotherapy vs. Pembrolizumab Monotherapy, to be showcased in Presidential Symposium at WCLC 2024	13/24/13	AQ
Summit Therapeutics Inc. - Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024	25/24/25	AQ
Summit Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results and Operational Progress Call on February 20, 2024	15/24/15	AQ
Summit Therapeutics to Present at Oppenheimer's 34th Annual Healthcare Life Sciences Conference	08/24/08	AQ
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2023	08/24/08	AQ
Akeso to Present at the 42nd Annual J.P. Morgan Healthcare Conference and Share Its Corporate & Innovative Clinical Development Roadmap	08/24/08	PR
Akeso Published Results from CD47 Antibody Ligufalimab in Combination with Azacitidine for Newly Diagnosed Higher-Risk Myelodysplastic Syndrome and Treatment-naive Acute Myeloid Leukemia at ASH 2023	18/23/18	AQ
Akeso Launches Construction of Shanghai Global R&D Center to Accelerate Its Innovation Globalization Strategy	28/23/28	PR
Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) Met Primary Endpoint of Progression-Free Survival in Phase III Trial for First-Line Treatment of Recurrent/Metastatic Cervical Cancer in All-Comer Patients	27/23/27	PR
Akeso's Cadonilimab (PD-1/CTLA-4) Phase III Trial Meets Primary Endpoint at Interim Analysis Demonstrating Strong Overall Survival Benefit as First-line Treatment in All-comer Patients with Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC)	07/23/07	PR
Summit Therapeutics Inc. - Ivonescimab's Novel Mechanism of Action Highlighting Cooperative Binding to be featured in Poster Presentation at SITC 2023	01/23/01	AQ
H. Jack West, MD, Renowned Oncologist and Lung Cancer Expert, Joins Summit Therapeutics as Vice President of Clinical Development	20/23/20	AQ
Phase 1a/1b Study Results of Akeso's PD-1/CTLA-4 Bispecific Antibody Published in Cell Reports Medicine, Highlighting Promising Efficacy in Solid Tumors Refractory/Relapsed to Standard Therapy	19/23/19	PR
Akeso Announced Completion of Patient Enrollment in Phase 3 Trial of Ivonescimab (PD-1/VEGF) versus Pembrolizumab in First-line PD-L1 Positive Advanced NSCLC	29/23/29	PR
Akeso Announced that Ivonescimab Granted Priority Review of NDA by China NMPA	25/23/25	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Akeso, Inc.

Equities

9926

KYG0146B1032

Biotechnology & Medical Research

Press Releases

Filters